University of Minnesota
Minneapolis, Minnesota, 55414, United States
NCT Number: NCT05826418
Recurrent Clostridioides difficle infection (rCDI) is a very significant problem in its own right and current fecal microbiota transplant (FMT) -based therapeutics will benefit from their optimization for this indication. It is likely that appropriate nutritional support coupled with microbiota-based drugs will yield superior clinical outcomes. However, both diet and gut microbiome are very complex. This project, which is based on a wealth of FMT experience, both clinical and investigational, over the past decade along with the novel techniques developed to identify dietary patterns and food groups that explain the most variation in gut microbiome, offers an ideal platform for performing systematic research in nutritional support that promotes gut microbiota health. The purpose is to Generate preliminary data with regards to tolerability of the Microbiota enhancing and nourishing diet (MEND) and its effects on the fecal microbiota in rCDI patients following FMT with the goal of developing larger clinical trials aimed to optimize post-FMT dietary management.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Minneapolis, Minnesota, 55414, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be asked to adhere to their randomized MEND diet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
Participants will be asked to adhere to their randomized mNICEdiet for 4 weeks and FMT. The FMT being offered is part of standard clinical care, as recommended by current practice guidelines. They will complete bi-weekly IBS symptom score questionnaires and stool samples collection from consent to week 4. Following the 4-week intervention period patients will not be asked to adhere to a study diet.
Time frame: 4 weeks
Diet acceptability questionnaire: Includes 7 questions each with minimum and maximum values (1 and 7) and higher scores mean better outcomes.
Time frame: intervention to 4 weeks
24-hr dietary recalls will be used to assure adherence with the study diet
Time frame: 1 week
Shannon diversity index
Time frame: 4 weeks
Shannon diversity index
Time frame: 3 months
Shannon diversity index
Time frame: 1 week
Using SourceTracker: which uses modeling based on 16S rDNA sequencing, is the measurement tool used to assess the measure
Time frame: 4 weeks
Using SourceTracker: which uses modeling based on 16S rDNA sequencing, is the measurement tool used to assess the measure
Time frame: 3 months
Using SourceTracker
Time frame: 1 week
Relative abundance of specific bacteria previously documented to be predictive of successful FMT outcomes with respect to CDI recurrence
Time frame: 4 weeks
Relative abundance of specific bacteria previously documented to be predictive of successful FMT outcomes with respect to CDI recurrence
Time frame: 3 months
Relative abundance of specific bacteria previously documented to be predictive of successful FMT outcomes with respect to CDI recurrence
University of Minnesota
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03462459
Bacterial Infections, Bacterial Infections and Mycoses
Madison, Wisconsin, United States
View Trial DetailsNCT05201079
Bacterial Infections, Bacterial Infections and Mycoses
Santander, Cantabria, Spain
View Trial DetailsNCT03834038
Bacterial Infections, Bacterial Infections and Mycoses
Victoria, British Columbia, Canada
View Trial DetailsNCT03497806
Bacterial Infections, Bacterial Infections and Mycoses
Scottsdale, Arizona, United States
View Trial Details